The prognostic role of Ki-67/MIB-1 in upper urinary-tract urothelial carcinomas: A systematic review and meta-analysis

Journal of Endourology

Volumn 29, Issue 11, 2015, Pages 1302-1308

  Lei, Ye ^a   Li, Zengbo ^a   Qi, Lin ^a   Tong, Shiyu ^a   Li, Bin ^b   He, Wei ^a   Chen, Minfeng ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN;

CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE FREE SURVIVAL; GENE OVEREXPRESSION; HUMAN; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SYSTEMATIC REVIEW; TRANSITIONAL CELL CARCINOMA; UPPER URINARY TRACT UROTHELIAL CARCINOMA; CARCINOMA, TRANSITIONAL CELL; KIDNEY NEOPLASMS; KIDNEY PELVIS; METABOLISM; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL ANALYSIS; URETERAL NEOPLASMS;

CARCINOMA, TRANSITIONAL CELL; DISEASE-FREE SURVIVAL; HUMANS; KI-67 ANTIGEN; KIDNEY NEOPLASMS; KIDNEY PELVIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; URETERAL NEOPLASMS;

EID: 84946746667     PISSN: 08927790     EISSN: 1557900X     Source Type: Journal    
DOI: 10.1089/end.2015.0420     Document Type: Review

References (40)

1. Zigeuner R, Pummer K. Urothelial carcinoma of the upper urinary tract: Surgical approach and prognostic factors. Eur Urol 2008; 53: 720-731
2. Munoz JJ, Ellison LM. Upper tract urothelial neoplasms: Incidence and survival during the last 2 decades. J Urol 2000; 164: 1523-1525
3. Brown GA, Busby JE, Wood CG, et al. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm?. BJU Int 2006; 98: 1176-1180
4. Chromecki TF, Bensalah K, Remzi M, et al. Prognostic factors for upper urinary tract urothelial carcinoma. Nat Rev Urol 2011; 8: 440-447
5. Lughezzani G, Burger M, Margulis V, et al. Prognostic factors in upper urinary tract urothelial carcinomas: A comprehensive review of the current literature. Eur Urol 2012; 62: 100-114
6. Eltz S, Comperat E, Cussenot O, Roupret M. Molecular and histological markers in urothelial carcinomas of the upper urinary tract. BJU Int 2008; 102: 532-535
7. Moreno SJ, Fernández PC, Mazuecos LM, et al. [Systematic review about the usefulness and prognostic value of the p53 oncoprotein and proliferation marker Ki-67 for upper urinary tract transitional cell carcinoma]. Arch Esp Urol 2004; 57: 327-335
8. Egger M, Smith GD, Phillips AN. Meta-Analysis: Principles and procedures. BMJ 1997; 315: 1533
9. Ku JH, Byun S-S, Jeong H, Kwak C, Kim HH, Lee SE. The role of p53 on survival of upper urinary tract urothelial carcinoma: A systematic review and meta-Analysis. Clin Genitourin Cancer 2013; 11: 221-228
10. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994; 69: 979
11. Chowdhury GM, Kojima K, Kanayama Ho, Tsuji M, Kurokawa Y, Kagawa S. The proliferation index of MIB-1 as a prognostic factor for patients with transitional cell carcinoma of the upper urinary tract. Cancer 1996; 78: 827-833
12. Kill IR. Localisation of the Ki-67 antigen within the nucleolus. Evidence for a fibrillarin-deficient region of the dense fibrillar component. J Cell Sci 1996; 109: 1253-1263
13. Masuda M, Iki M, Takano Y, et al. Prognostic significance of Ki-67 labeling index in urothelial tumors of the renal pelvis and ureter. J Urol 1996; 155: 1877-1881
14. Kamai T, Takagi K, Asami H, Ito Y, Arai K, Yoshida KI Prognostic significance of p27Kip1 and Ki-67 expression in carcinoma of the renal pelvis and ureter.BJU Int 2000 86 14-19
15. van Rhijn BW, Vis AN, van der Kwast TH, et al. Molecular grading of urothelial cell carcinomawith fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. JClinOncol 2003; 21: 1912-1921
16. Fromont G, Roupret M, Amira N, et al. Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma. Eur Urol 2005; 48: 764-770
17. Kamijima S, Tobe T, Suyama T, et al. The prognostic value of p53, Ki-67 and matrix metalloproteinases MMP-2 and MMP-9 in transitional cell carcinoma of the renal pelvis and ureter. Int J Urol 2005; 12: 941-947
18. CHEN M, XU, Dan-feng, CUI, Xin-gang, GAO, Yi, REN Ji-zhong. Multivariate analysis of prognosis of patients with upper urinary tract transitional cell carcinoma. Acad J Second Mil Med Univ 2008; 29: 1217-1220. Chinese
19. Joung JY, Yang SO, Jeong IG, et al. Identification of immunohistochemical factors that predict the synchronous or metachronous development of bladder tumors in patients with upper urinary tract tumors. Urol Int 2008; 81: 306-311
20. Tsujimoto Y, Komori K, Tsujimoto M, et al. [Immunohistochemical studies of p53, Ki-67, E-cadherin and beta-catenin on renal pelvic and ureteral cancers]. Nihon Hinyokika Gakkai Zasshi 2008; 99: 1-6
21. Jeon HG, Jeong IG, Bae J, et al. Expression of Ki-67 and COX-2 in patients with upper urinary tract urothelial carcinoma. Urology 2010; 76: 513. e7-e12
22. Lyle SR, Hsieh C-C, Fernandez CA, Shuber AP. Molecular grading of tumors of the upper urothelial tract using FGFR3 mutation status identifies patients with favorable prognosis. Res Rep Urol 2012; 4: 65
23. Garc?á-Tello A, Angulo J, Andrés G, Ramón d FF, Sánchez-Chapado M, López J. Impact of p53, MIB-1 and PECAM-1 expression on the prognosis of urothelial carcinoma of the renal pelvis. Actas Urol Esp 2014; 38: 506-514
24. Gerdes J, Li L, Schlueter C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-Associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991; 138: 867
25. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005; 23: 7212-7220
26. van Dierendonck JH, Keijzer R, van de Velde CJ, Cornelisse CJ. Nuclear distribution of the Ki-67 antigen during the cell cycle: Comparison with growth fraction in human breast cancer cells. Cancer Res 1989; 49: 2999-3006
27. Heidebrecht H, Buck F, Haas K, Wacker H, Parwaresch R. Monoclonal antibodies Ki-S3 and Ki-S5 yield new data on the "Ki-67" proteins. Cell Prolif 1996; 29: 413-425
28. Starborg M, Gell K, Brundell E, Hoog C. The murine Ki-67 cell proliferation antigen accumulates in the nucleolar and heterochromatic regions of interphase cells and at the periphery of the mitotic chromosomes in a process essential for cell cycle progression. J Cell Sci 1996; 109: 143-153
29. Nakopoulou L, Vourlakou C, Zervas A, Tzonou A, Gakiopoulou H, Dimopoulos M-A. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum Pathol 1998; 29: 146-154
30. Rioux-Leclercq N, Turlin B, Bansard J-Y, et al. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology 2000; 55: 501-505
31. de Azambuja E, Cardoso F, de Castro G, et al. Ki-67 as prognostic marker in early breast cancer: A meta-Analysis of published studies involving 12 155 patients. Br J Cancer 2007; 96: 1504-1513
32. Li R, Heydon K, Hammond ME, et al. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy an analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res 2004; 10: 4118-4124
33. Ho DM-T, Hsu C-Y, Chiang H. MIB-1 labeling index as a prognostic indicator for survival in patients with FIGO stage IB squamous cell carcinoma of the cervix. Gynecol Oncol 2000; 76: 97-102
34. Lundin J, Nordling S, Von Boguslawsky K, Roberts PJ, Haglund C. Prognostic value of Ki-67 expression, ploidy and S-phase fraction in patients with pancreatic cancer. Anticancer Res 1994; 15: 2659-2668
35. Martin B, Paesmans M, Mascaux C, et al. Ki-67 expression and patients survival in lung cancer: Systematic review of the literature with meta-Analysis. Br J Cancer 2004; 91: 2018-2025
36. Silva SD, Agostini M, Nishimoto IN, et al. Expression of fatty acid synthase, ErbB2 and Ki-67 in head and neck squamous cell carcinoma. A clinicopathological study. Oral Oncol 2004; 40: 688-696
37. Hoos A, Stojadinovic A, Mastorides S, et al. High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas. Cancer 2001; 92: 869-874
38. Lopez F, Belloc F, Lacombe F, et al. Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. Cytometry 1991; 12: 42-49
39. Braun N, Papadopoulos T, Müller-Hermelink HK. Cell cycle dependent distribution of the proliferation-Associated Ki-67 antigen in human embryonic lung cells. Virchows Arch B 1988; 56: 25-33
40. Spyratos F, Ferrero-Poüs M, Trassard M, et al. Correlation between MIB-1 and other proliferation markers. Cancer 2002; 94: 2151-2159